Observational Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Apr 26, 2022; 10(12): 3739-3753
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3739
Table 3 Univariable Cox regression analysis of various outcomes
Characteristics
PFS
OS
CFI
HR
95%CI
P value
HR
95%CI
P value
HR
95%CI
P value
Age
< 50 yrs0.929(0.469, 1.839)0.8320.684(0.276, 1.694)0.4121.06(0.538, 2.092)0.866
≥ 50 yrsReferenceReferenceReference
Pathological type
High-grade serous carcinomaReferenceReferenceReference
Endometrioid carcinoma0.523(0.178, 1.543)0.2410.697(0.199, 2.439)0.5720.32(0.107, 0.956)0.041
Clear cell carcinoma1.107(0.417, 2.942)0.8380.788(0.224, 2.769)0.710.991(0.368, 2.67)0.985
Mucinous carcinoma0.491(0.065, 3.706)0.4911.957(0.249, 15.399)0.5240.238(0.031, 1.849)0.17
Mixed type6.929(0.803, 59.809)0.07811.285(1.157, 110.099)0.0372.559(0.327, 20.016)0.371
Pathological classification
Highly differentiated0.822(0.249, 2.713)0.7481.427(0.413, 4.931)0.5740.644(0.193, 2.154)0.475
Moderately differentiated0.583(0.137, 2.474)0.4640.878(0.198, 3.881)0.8630.348(0.082, 1.477)0.152
Poorly differentiatedReferenceReferenceReference
Number of previous surgery
03.676(0.464, 29.112)0.2186.505(0.755, 56.05)0.0888.71(0.969, 78.245)0.053
1ReferenceReferenceReference
20.807(0.276, 2.358)0.6960.961(0.223, 4.151)0.9581.02(0.351, 2.964)0.97
30.922(0.124, 6.864)0.937///1.251(0.167, 9.374)0.827
Number of previous chemotherapy lines
1ReferenceReferenceReference
20.639(0.272, 1.504)0.3050.573(0.165, 1.987)0.3810.974(0.426, 2.229)0.951
≥ 30.81(0.307, 2.142)0.6721.863(0.592, 5.865)0.2881.182(0.476, 2.935)0.719
FIGO staging of the first surgery
I1.507(0.345, 6.58)0.5861.634(0.358, 7.466)0.5262.678(0.577, 12.437)0.209
II0.752(0.352, 1.606)0.4621.244(0.512, 3.027)0.630.672(0.319, 1.415)0.295
IIIReferenceReferenceReference
IV0.419(0.097, 1.819)0.246///0.525(0.12, 2.285)0.39
Residual lesions of the first surgery
R0ReferenceReferenceReference
R11.122(0.505, 2.49)0.7780.936(0.355, 2.469)0.8941.059(0.484, 2.32)0.885
R21.071(0.461, 2.489)0.8740.422(0.119, 1.492)0.1811.055(0.454, 2.456)0.9
Neoadjuvant chemotherapy0.629(0.278,1.423)0.2661.081(0.394, 2.965)0.8790.717(0.329, 1.56)0.401
Remission time of chemotherapy before this secondary surgery
≤ 3 mo1.338(0.68, 2.631)0.3990.767(0.322, 1.827)0.5491.022(0.519, 2.014)0.95
3-6 moReferenceReferenceReference
Type of platinum resistance
SecondaryReferenceReferenceReference
Primary0.982(0.471, 2.048)0.9620.843(0.281, 2.529)0.7611.354(0.647, 2.833)0.421
Preoperative ECOG score
0-1ReferenceReferenceReference
20.643(0.226, 1.830)0.4080.654(0.184, 2.323)0.5110.575(0.221, 1.497)0.257
Location of recurrent lesions
Pelvic cavity0.799(0.305, 2.091)0.6480.981(0.314, 3.062)0.9730.661(0.239, 1.827)0.425
Abdominopelvic cavityReference ReferenceReference
Pelvic/abdominal cavity + retroperitoneal0.818(0.391, 1.711)0.5940.728(0.279, 1.9)0.5160.867(0.422, 1.78)0.697
Residual lesions of this secondary surgery
R0ReferenceReferenceReference
R1-R23.29(1.511, 7.162)0.0032.65(1.115, 6.298)0.0272.777(1.108, 4.679)0.025
Intraoperative organ resection1.251(0.616, 2.542)0.5361.19(0.485, 2.921)0.7051.586(0.772, 3.257)0.21
Bleeding amount
≤ 400 mLReferenceReferenceReference
401-800 mL0.668(0.309, 1.444)0.3050.634(0.222, 1.807)0.3930.963(0.459, 2.021)0.92
> 800 mL2.862(1.048, 7.813)0.042.422(0.83, 7.072)0.1061.601(0.623, 4.111)0.328
Perioperative complications0.669(0.289, 1.548)0.3481.355(0.527, 3.478)0.5280.713(0.307, 1.656)0.432
Postoperative chemotherapy
No5.027(1.061, 23.828)0.04257.66(5.099, 651.995)0.001///
YesReferenceReference///
Postoperative use of targeted drugs0.518(0.178, 1.504)0.2260.436(0.101, 1.887)0.2670.745(0.277, 2.003)0.56
Postoperative hospital stay
≤ 10 dReferenceReferenceReference
11-20 d1.212(0.573, 2.567)0.6152.411(0.963, 6.037)0.061.104(0.524, 2.328)0.795
> 20 d1.911(0.44, 8.308)0.3883.98(0.853, 18.563)0.0793.246(0.695, 15.154)0.134